RT Journal Article
SR Electronic
T1 Alternative dosing regimens of GLP-1 receptor agonists may reduce costs and maintain weight loss efficacy
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.11.27.24318093
DO 10.1101/2024.11.27.24318093
A1 Cengiz, Anıl
A1 Wu, Calvin C.
A1 Lawley, Sean D.
YR 2024
UL http://medrxiv.org/content/early/2024/12/01/2024.11.27.24318093.abstract
AB Aims To discover alternative dosing regimens of incretin mimetics that simultaneously reduce costs and maintain weight loss efficacy. As a secondary objective, we used our results to explore how allocating a limited incretin mimetics budget could affect public health on a national scale.Materials and Methods We used mathematical modeling and simulation of semaglutide and tirzepatide. For semaglutide, we used a recent pharmacokinetic (PK) and pharmacodynamic (PD) model. For tirzepatide, we used a recent PK model and modeled PD by reparameterizing the semaglutide PD model to fit tirzepatide clinical data.Results Reducing dose frequency does not commensurately reduce weight loss. For example, merely switching from one dose per week (q1wk) to one dose every two weeks (q2wk) maintains roughly 75% of the weight loss. Furthermore, if the decrease in dose frequency involves an appropriate increase in dose size, then approximately 100% of the weight loss is maintained. In addition, we compared offering incretin mimetics to (1) a fraction of obese US adults with q1wk dosing versus (2) twice as many obese US adults with q2wk dosing. Though scenarios (1) and (2) require the same budget, our analysis suggests that (2) reduces national obesity and mortality to a much greater degree.Conclusion Our study highlights the potential utility of alternative dosing regimens of incretin mimetics. Compared to standard once-weekly dosing, costs can be halved and weight loss maintained. These cost-saving results have implications for patients, physicians, insurers, and governments.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSDL and AC were supported by the National Science Foundation (Grant Nos.\ CAREER DMS-1944574 and DMS-2325258)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:http://www.nejm.org/doi/10.1056/NEJMoa2032183 http://www.nejm.org/doi/10.1056/NEJMoa2206038I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe computer code which implements the mathematical model and creates the relevant figures is publicly available at https://github.com/seanlawley/glp1.